Selected research
Industry Growth & Trends
Global Sickle Cell Disease Drug Industry Growth and Trends Forecast to 2032
Market perspective
The global Sickle Cell Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Sickle Cell Disease Drug include Global Blood Therapeutics Inc, Gilead Sciences Inc, Genethon SA, Gamida Cell Ltd, Errant Gene Therapeutics LLC, Editas Medicine Inc, Daiichi Sankyo Co Ltd, CSL Ltd and CRISPR Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Sickle Cell Disease Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Sickle Cell Disease Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Sickle Cell Disease Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Sickle Cell Disease Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Sickle Cell Disease Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Sickle Cell Disease Drug Market by Company
Global Blood Therapeutics Inc
Gilead Sciences Inc
Genethon SA
Gamida Cell Ltd
Errant Gene Therapeutics LLC
Editas Medicine Inc
Daiichi Sankyo Co Ltd
CSL Ltd
CRISPR Therapeutics
Calimmune Inc
Bristol-Myers Squibb Co
bluebird bio Inc
Bioverativ Inc
Bio Products Laboratory Ltd
ArQule Inc
Annexin Pharmaceuticals AB
Angiocrine Bioscience Inc
Addmedica SAS
Acceleron Pharma Inc
Sickle Cell Disease Drug Segment by Type
CAL-H
DRX-194
CTX-001
BIVV-003
ARQ-092
Others
Sickle Cell Disease Drug Segment by Application
Hospital
Clinic
Others
Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
List of Tables
Table 1. Major Company of CAL-H
Table 2. Major Company of DRX-194
Table 3. Major Company of CTX-001
Table 4. Major Company of BIVV-003
Table 5. Major Company of ARQ-092
Table 6. Major Company of Others
Table 7. Global Sickle Cell Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 8. Global Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units)
Table 9. Global Sickle Cell Disease Drug Sales Market Share in Volume by Type (2021-2026)
Table 10. Global Sickle Cell Disease Drug Sales by Type (2021-2026) & (US$ Million)
Table 11. Global Sickle Cell Disease Drug Sales Market Share in Value by Type (2021-2026)
Table 12. Global Sickle Cell Disease Drug Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Sickle Cell Disease Drug Sales by Type (2027-2032) & (K Units)
Table 14. Global Sickle Cell Disease Drug Sales Market Share in Volume by Type (2027-2032)
Table 15. Global Sickle Cell Disease Drug Sales by Type (2027-2032) & (US$ Million)
Table 16. Global Sickle Cell Disease Drug Sales Market Share in Value by Type (2027-2032)
Table 17. Global Sickle Cell Disease Drug Price by Type (2027-2032) & (US$/Unit)
Table 18. North America Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units)
Table 19. North America Sickle Cell Disease Drug Sales by Type (2021-2026) & (US$ Million)
Table 20. Europe Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units)
Table 21. Europe Sickle Cell Disease Drug Sales by Type (2021-2026) & (US$ Million)
Table 22. Asia-Pacific Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units)
Table 23. Asia-Pacific Sickle Cell Disease Drug Sales by Type (2021-2026) & (US$ Million)
Table 24. Latin America Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units)
Table 25. Latin America Sickle Cell Disease Drug Sales by Type (2021-2026) & (US$ Million)
Table 26. Middle East and Africa Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units)
Table 27. Middle East and Africa Sickle Cell Disease Drug Sales by Type (2021-2026) & (US$ Million)
Table 28. Sickle Cell Disease Drug Industry Trends
Table 29. Sickle Cell Disease Drug Industry Drivers
Table 30. Sickle Cell Disease Drug Industry Opportunities and Challenges
Table 31. Sickle Cell Disease Drug Industry Restraints
Table 32. Global Sickle Cell Disease Drug Sales Revenue by Company (US$ Million) & (2021-2026)
Table 33. Global Sickle Cell Disease Drug Revenue Market Share by Company (2021-2026)
Table 34. Global Sickle Cell Disease Drug Sales by Company (2021-2026) & (K Units)
Table 35. Global Sickle Cell Disease Drug Sales Share by Company (2021-2026)
Table 36. Global Sickle Cell Disease Drug Market Price by Company (2021-2026) & (US$/Unit)
Table 37. Global Sickle Cell Disease Drug Industry Company Ranking, 2024 VS 2025 VS 2026
Table 38. Global Sickle Cell Disease Drug Major Company Production Sites and Headquarters
Table 39. Global Sickle Cell Disease Drug Company, Product Type & Application
Table 40. Global Sickle Cell Disease Drug Company Establishment Date
Table 41. Global Company Market Concentration Ratio (CR5 and HHI)
Table 42. Global Sickle Cell Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 43. Global Sickle Cell Disease Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032
Table 44. Global Sickle Cell Disease Drug Sales by Region (2021-2026) & (K Units)
Table 45. Global Sickle Cell Disease Drug Sales Market Share in Volume by Region (2021-2026)
Table 46. Global Sickle Cell Disease Drug Sales by Region (2021-2026) & (US$ Million)
Table 47. Global Sickle Cell Disease Drug Sales Market Share in Value by Region (2021-2026)
Table 48. Global Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 49. Global Sickle Cell Disease Drug Sales by Region (2027-2032) & (K Units)
Table 50. Global Sickle Cell Disease Drug Sales Market Share in Volume by Region (2027-2032)
Table 51. Global Sickle Cell Disease Drug Sales by Region (2027-2032) & (US$ Million)
Table 52. Global Sickle Cell Disease Drug Sales Market Share in Value by Region (2027-2032)
Table 53. Global Sickle Cell Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032)
Table 54. Global Sickle Cell Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 55. Global Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units)
Table 56. Global Sickle Cell Disease Drug Sales Market Share in Volume by Application (2021-2026)
Table 57. Global Sickle Cell Disease Drug Sales by Application (2021-2026) & (US$ Million)
Table 58. Global Sickle Cell Disease Drug Sales Market Share in Value by Application (2021-2026)
Table 59. Global Sickle Cell Disease Drug Price by Application (2021-2026) & (US$/Unit)
Table 60. Global Sickle Cell Disease Drug Sales by Application (2027-2032) & (K Units)
Table 61. Global Sickle Cell Disease Drug Sales Market Share in Volume by Application (2027-2032)
Table 62. Global Sickle Cell Disease Drug Sales by Application (2027-2032) & (US$ Million)
Table 63. Global Sickle Cell Disease Drug Sales Market Share in Value by Application (2027-2032)
Table 64. Global Sickle Cell Disease Drug Price by Application (2027-2032) & (US$/Unit)
Table 65. North America Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units)
Table 66. North America Sickle Cell Disease Drug Sales by Application (2021-2026) & (US$ Million)
Table 67. Europe Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units)
Table 68. Europe Sickle Cell Disease Drug Sales by Application (2021-2026) & (US$ Million)
Table 69. Asia-Pacific Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units)
Table 70. Asia-Pacific Sickle Cell Disease Drug Sales by Application (2021-2026) & (US$ Million)
Table 71. Latin America Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units)
Table 72. Latin America Sickle Cell Disease Drug Sales by Application (2021-2026) & (US$ Million)
Table 73. Middle East and Africa Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units)
Table 74. Middle East and Africa Sickle Cell Disease Drug Sales by Application (2021-2026) & (US$ Million)
Table 75. Global Blood Therapeutics Inc Company Information
Table 76. Global Blood Therapeutics Inc Business Overview
Table 77. Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio
Table 79. Global Blood Therapeutics Inc Recent Development
Table 80. Gilead Sciences Inc Company Information
Table 81. Gilead Sciences Inc Business Overview
Table 82. Gilead Sciences Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio
Table 84. Gilead Sciences Inc Recent Development
Table 85. Genethon SA Company Information
Table 86. Genethon SA Business Overview
Table 87. Genethon SA Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. Genethon SA Sickle Cell Disease Drug Product Portfolio
Table 89. Genethon SA Recent Development
Table 90. Gamida Cell Ltd Company Information
Table 91. Gamida Cell Ltd Business Overview
Table 92. Gamida Cell Ltd Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio
Table 94. Gamida Cell Ltd Recent Development
Table 95. Errant Gene Therapeutics LLC Company Information
Table 96. Errant Gene Therapeutics LLC Business Overview
Table 97. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio
Table 99. Errant Gene Therapeutics LLC Recent Development
Table 100. Editas Medicine Inc Company Information
Table 101. Editas Medicine Inc Business Overview
Table 102. Editas Medicine Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio
Table 104. Editas Medicine Inc Recent Development
Table 105. Daiichi Sankyo Co Ltd Company Information
Table 106. Daiichi Sankyo Co Ltd Business Overview
Table 107. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio
Table 109. Daiichi Sankyo Co Ltd Recent Development
Table 110. CSL Ltd Company Information
Table 111. CSL Ltd Business Overview
Table 112. CSL Ltd Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. CSL Ltd Sickle Cell Disease Drug Product Portfolio
Table 114. CSL Ltd Recent Development
Table 115. CRISPR Therapeutics Company Information
Table 116. CRISPR Therapeutics Business Overview
Table 117. CRISPR Therapeutics Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio
Table 119. CRISPR Therapeutics Recent Development
Table 120. Calimmune Inc Company Information
Table 121. Calimmune Inc Business Overview
Table 122. Calimmune Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. Calimmune Inc Sickle Cell Disease Drug Product Portfolio
Table 124. Calimmune Inc Recent Development
Table 125. Bristol-Myers Squibb Co Company Information
Table 126. Bristol-Myers Squibb Co Business Overview
Table 127. Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio
Table 129. Bristol-Myers Squibb Co Recent Development
Table 130. bluebird bio Inc Company Information
Table 131. bluebird bio Inc Business Overview
Table 132. bluebird bio Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. bluebird bio Inc Sickle Cell Disease Drug Product Portfolio
Table 134. bluebird bio Inc Recent Development
Table 135. Bioverativ Inc Company Information
Table 136. Bioverativ Inc Business Overview
Table 137. Bioverativ Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. Bioverativ Inc Sickle Cell Disease Drug Product Portfolio
Table 139. Bioverativ Inc Recent Development
Table 140. Bio Products Laboratory Ltd Company Information
Table 141. Bio Products Laboratory Ltd Business Overview
Table 142. Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 143. Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio
Table 144. Bio Products Laboratory Ltd Recent Development
Table 145. ArQule Inc Company Information
Table 146. ArQule Inc Business Overview
Table 147. ArQule Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 148. ArQule Inc Sickle Cell Disease Drug Product Portfolio
Table 149. ArQule Inc Recent Development
Table 150. Annexin Pharmaceuticals AB Company Information
Table 151. Annexin Pharmaceuticals AB Business Overview
Table 152. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 153. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio
Table 154. Annexin Pharmaceuticals AB Recent Development
Table 155. Angiocrine Bioscience Inc Company Information
Table 156. Angiocrine Bioscience Inc Business Overview
Table 157. Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 158. Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio
Table 159. Angiocrine Bioscience Inc Recent Development
Table 160. Addmedica SAS Company Information
Table 161. Addmedica SAS Business Overview
Table 162. Addmedica SAS Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 163. Addmedica SAS Sickle Cell Disease Drug Product Portfolio
Table 164. Addmedica SAS Recent Development
Table 165. Acceleron Pharma Inc Company Information
Table 166. Acceleron Pharma Inc Business Overview
Table 167. Acceleron Pharma Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 168. Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio
Table 169. Acceleron Pharma Inc Recent Development
Table 170. North America Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 171. North America Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 172. North America Sickle Cell Disease Drug Sales Market Share by Country (2021-2026)
Table 173. North America Sickle Cell Disease Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 174. North America Sickle Cell Disease Drug Sales Market Share Forecast by Country (2027-2032)
Table 175. North America Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 176. North America Sickle Cell Disease Drug Market Size by Country (2021-2026) & (US$ Million)
Table 177. North America Sickle Cell Disease Drug Market Share by Country (2021-2026)
Table 178. North America Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 179. North America Sickle Cell Disease Drug Market Share Forecast by Country (2027-2032)
Table 180. Europe Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 181. Europe Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 182. Europe Sickle Cell Disease Drug Sales Market Share by Country (2021-2026)
Table 183. Europe Sickle Cell Disease Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 184. Europe Sickle Cell Disease Drug Sales Market Share Forecast by Country (2027-2032)
Table 185. Europe Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 186. Europe Sickle Cell Disease Drug Market Size by Country (2021-2026) & (US$ Million)
Table 187. Europe Sickle Cell Disease Drug Market Share by Country (2021-2026)
Table 188. Europe Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 189. Europe Sickle Cell Disease Drug Market Share Forecast by Country (2027-2032)
Table 190. Asia-Pacific Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 191. Asia-Pacific Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 192. Asia-Pacific Sickle Cell Disease Drug Sales Market Share by Country (2021-2026)
Table 193. Asia-Pacific Sickle Cell Disease Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 194. Asia-Pacific Sickle Cell Disease Drug Sales Market Share Forecast by Country (2027-2032)
Table 195. Asia-Pacific Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 196. Asia-Pacific Sickle Cell Disease Drug Market Size by Country (2021-2026) & (US$ Million)
Table 197. Asia-Pacific Sickle Cell Disease Drug Market Share by Country (2021-2026)
Table 198. Asia-Pacific Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 199. Asia-Pacific Sickle Cell Disease Drug Market Share Forecast by Country (2027-2032)
Table 200. Latin America Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 201. Latin America Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 202. Latin America Sickle Cell Disease Drug Sales Market Share by Country (2021-2026)
Table 203. Latin America Sickle Cell Disease Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 204. Latin America Sickle Cell Disease Drug Sales Market Share Forecast by Country (2027-2032)
Table 205. Latin America Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 206. Latin America Sickle Cell Disease Drug Market Size by Country (2021-2026) & (US$ Million)
Table 207. Latin America Sickle Cell Disease Drug Market Share by Country (2021-2026)
Table 208. Latin America Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 209. Latin America Sickle Cell Disease Drug Market Share Forecast by Country (2027-2032)
Table 210. Middle East and Africa Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 211. Middle East and Africa Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 212. Middle East and Africa Sickle Cell Disease Drug Sales Market Share by Country (2021-2026)
Table 213. Middle East and Africa Sickle Cell Disease Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 214. Middle East and Africa Sickle Cell Disease Drug Sales Market Share Forecast by Country (2027-2032)
Table 215. Middle East and Africa Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 216. Middle East and Africa Sickle Cell Disease Drug Market Size by Country (2021-2026) & (US$ Million)
Table 217. Middle East and Africa Sickle Cell Disease Drug Market Share by Country (2021-2026)
Table 218. Middle East and Africa Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 219. Middle East and Africa Sickle Cell Disease Drug Market Share Forecast by Country (2027-2032)
Table 220. Key Raw Materials
Table 221. Raw Materials Key Suppliers
Table 222. Sickle Cell Disease Drug Distributors List
Table 223. Sickle Cell Disease Drug Customers List
Table 224. Research Programs/Design for This Report
Table 225. Authors List of This Report
Table 226. Secondary Sources
Table 227. Primary Sources
List of Figures
Figure 1. Sickle Cell Disease Drug Image
Figure 2. Global Sickle Cell Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Sickle Cell Disease Drug Sales (2021-2032) & (K Units)
Figure 5. CAL-H Image
Figure 6. Global CAL-H Sales YoY Growth (2021-2032) & (K Units)
Figure 7. DRX-194 Image
Figure 8. Global DRX-194 Sales YoY Growth (2021-2032) & (K Units)
Figure 9. CTX-001 Image
Figure 10. Global CTX-001 Sales YoY Growth (2021-2032) & (K Units)
Figure 11. BIVV-003 Image
Figure 12. Global BIVV-003 Sales YoY Growth (2021-2032) & (K Units)
Figure 13. ARQ-092 Image
Figure 14. Global ARQ-092 Sales YoY Growth (2021-2032) & (K Units)
Figure 15. Others Image
Figure 16. Global Others Sales YoY Growth (2021-2032) & (K Units)
Figure 17. Global Sickle Cell Disease Drug Market Size Overview by Type (2021-2032) & (US$ Million)
Figure 18. Global Sickle Cell Disease Drug Market Share by Type 2025 VS 2032
Figure 19. North America Sickle Cell Disease Drug Sales Market Share in Volume by Type in 2025
Figure 20. North America Sickle Cell Disease Drug Sales Market Share in Value by Type in 2025
Figure 21. Europe Sickle Cell Disease Drug Sales Market Share in Volume by Type in 2025
Figure 22. Europe Sickle Cell Disease Drug Sales Market Share in Value by Type in 2025
Figure 23. Asia-Pacific Sickle Cell Disease Drug Sales Market Share in Volume by Type in 2025
Figure 24. Asia-Pacific Sickle Cell Disease Drug Sales Market Share in Value by Type in 2025
Figure 25. Latin America Sickle Cell Disease Drug Sales Market Share in Volume by Type in 2025
Figure 26. Latin America Sickle Cell Disease Drug Sales Market Share in Value by Type in 2025
Figure 27. Middle East and Africa Sickle Cell Disease Drug Sales Market Share in Volume by Type in 2025
Figure 28. Middle East and Africa Sickle Cell Disease Drug Sales Market Share in Value by Type in 2025
Figure 29. Global Top 5 and 10 Sickle Cell Disease Drug Players Market Share by Revenue in 2025
Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 31. Hospital Image
Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (K Units)
Figure 33. Clinic Image
Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (K Units)
Figure 35. Others Image
Figure 36. Global Others Sales YoY Growth (2021-2032) & (K Units)
Figure 37. Global Sickle Cell Disease Drug Market Size Overview by Application (2021-2032) & (US$ Million)
Figure 38. Global Sickle Cell Disease Drug Market Share by Application 2025 VS 2032
Figure 39. North America Sickle Cell Disease Drug Sales Market Share in Volume by Application in 2025
Figure 40. North America Sickle Cell Disease Drug Sales Market Share in Value by Application in 2025
Figure 41. Europe Sickle Cell Disease Drug Sales Market Share in Volume by Application in 2025
Figure 42. Europe Sickle Cell Disease Drug Sales Market Share in Value by Application in 2025
Figure 43. Asia-Pacific Sickle Cell Disease Drug Sales Market Share in Volume by Application in 2025
Figure 44. Asia-Pacific Sickle Cell Disease Drug Sales Market Share in Value by Application in 2025
Figure 45. Latin America Sickle Cell Disease Drug Sales Market Share in Volume by Application in 2025
Figure 46. Latin America Sickle Cell Disease Drug Sales Market Share in Value by Application in 2025
Figure 47. Middle East and Africa Sickle Cell Disease Drug Sales Market Share in Volume by Application in 2025
Figure 48. Middle East and Africa Sickle Cell Disease Drug Sales Market Share in Value by Application in 2025
Figure 49. North America Sickle Cell Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 50. North America Sickle Cell Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032
Figure 51. North America Sickle Cell Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 52. North America Sickle Cell Disease Drug Market Share by Country: 2021 VS 2025 VS 2032
Figure 53. Europe Sickle Cell Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 54. Europe Sickle Cell Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032
Figure 55. Europe Sickle Cell Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 56. Europe Sickle Cell Disease Drug Market Share by Country: 2021 VS 2025 VS 2032
Figure 57. Asia-Pacific Sickle Cell Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 58. Asia-Pacific Sickle Cell Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032
Figure 59. Asia-Pacific Sickle Cell Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 60. Asia-Pacific Sickle Cell Disease Drug Market Share by Country: 2021 VS 2025 VS 2032
Figure 61. Latin America Sickle Cell Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 62. Latin America Sickle Cell Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032
Figure 63. Latin America Sickle Cell Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 64. Latin America Sickle Cell Disease Drug Market Share by Country: 2021 VS 2025 VS 2032
Figure 65. Middle East and Africa Sickle Cell Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 66. Middle East and Africa Sickle Cell Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032
Figure 67. Middle East and Africa Sickle Cell Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 68. Middle East and Africa Sickle Cell Disease Drug Market Share by Country: 2021 VS 2025 VS 2032
Figure 69. Sickle Cell Disease Drug Value Chain
Figure 70. Key Raw Materials Price
Figure 71. Manufacturing Cost Structure
Figure 72. Sickle Cell Disease Drug Production Mode & Process
Figure 73. Direct Comparison with Distribution Share
Figure 74. Distributors Profiles
Figure 75. Years Considered
Figure 76. Research Process
Figure 77. Key Executives Interviewed
Scope & coverage.
Types
- CAL-H
- DRX-194
- CTX-001
- BIVV-003
- ARQ-092
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Global Blood Therapeutics Inc
- Gilead Sciences Inc
- Genethon SA
- Gamida Cell Ltd
- Errant Gene Therapeutics LLC
- Editas Medicine Inc
- Daiichi Sankyo Co Ltd
- CSL Ltd
- CRISPR Therapeutics
- Calimmune Inc
- Bristol-Myers Squibb Co
- bluebird bio Inc
- Bioverativ Inc
- Bio Products Laboratory Ltd
- ArQule Inc
- Annexin Pharmaceuticals AB
- Angiocrine Bioscience Inc
- Addmedica SAS
- Acceleron Pharma Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Sickle Cell Disease Drug Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Sickle Cell Disease Drug Sales Estimates and Forecasts (2021-2032)
- 1.3 Sickle Cell Disease Drug Market by Type
- 1.3.1 CAL-H
- 1.3.2 DRX-194
- 1.3.3 CTX-001
- 1.3.4 BIVV-003
- 1.3.5 ARQ-092
- 1.3.6 Others
- 1.4 Global Sickle Cell Disease Drug Market Size by Type
- 1.4.1 Global Sickle Cell Disease Drug Market Size Overview by Type (2021-2032)
- 1.4.2 Global Sickle Cell Disease Drug Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Sickle Cell Disease Drug Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Sickle Cell Disease Drug Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Sickle Cell Disease Drug Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Sickle Cell Disease Drug Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Sickle Cell Disease Drug Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Sickle Cell Disease Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Sickle Cell Disease Drug Industry Trends
- 2.2 Sickle Cell Disease Drug Industry Drivers
- 2.3 Sickle Cell Disease Drug Industry Opportunities and Challenges
- 2.4 Sickle Cell Disease Drug Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Sickle Cell Disease Drug Revenue (2021-2026)
- 3.2 Global Top Players by Sickle Cell Disease Drug Sales (2021-2026)
- 3.3 Global Top Players by Sickle Cell Disease Drug Price (2021-2026)
- 3.4 Global Sickle Cell Disease Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Sickle Cell Disease Drug Major Company Production Sites & Headquarters
- 3.6 Global Sickle Cell Disease Drug Company, Product Type & Application
- 3.7 Global Sickle Cell Disease Drug Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Sickle Cell Disease Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Sickle Cell Disease Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Sickle Cell Disease Drug Tier 1, Tier 2, and Tier 3
4 Sickle Cell Disease Drug Regional Status and Outlook
- 4.1 Global Sickle Cell Disease Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Sickle Cell Disease Drug Historic Market Size by Region
- 4.2.1 Global Sickle Cell Disease Drug Sales in Volume by Region (2021-2026)
- 4.2.2 Global Sickle Cell Disease Drug Sales in Value by Region (2021-2026)
- 4.2.3 Global Sickle Cell Disease Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Sickle Cell Disease Drug Forecasted Market Size by Region
- 4.3.1 Global Sickle Cell Disease Drug Sales in Volume by Region (2027-2032)
- 4.3.2 Global Sickle Cell Disease Drug Sales in Value by Region (2027-2032)
- 4.3.3 Global Sickle Cell Disease Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Sickle Cell Disease Drug by Application
- 5.1 Sickle Cell Disease Drug Market by Application
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Sickle Cell Disease Drug Market Size by Application
- 5.2.1 Global Sickle Cell Disease Drug Market Size Overview by Application (2021-2032)
- 5.2.2 Global Sickle Cell Disease Drug Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Sickle Cell Disease Drug Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Sickle Cell Disease Drug Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Sickle Cell Disease Drug Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Sickle Cell Disease Drug Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Sickle Cell Disease Drug Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Sickle Cell Disease Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Global Blood Therapeutics Inc
- 6.1.1 Global Blood Therapeutics Inc Company Information
- 6.1.2 Global Blood Therapeutics Inc Business Overview
- 6.1.3 Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio
- 6.1.5 Global Blood Therapeutics Inc Recent Developments
- 6.2 Gilead Sciences Inc
- 6.2.1 Gilead Sciences Inc Company Information
- 6.2.2 Gilead Sciences Inc Business Overview
- 6.2.3 Gilead Sciences Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio
- 6.2.5 Gilead Sciences Inc Recent Developments
- 6.3 Genethon SA
- 6.3.1 Genethon SA Company Information
- 6.3.2 Genethon SA Business Overview
- 6.3.3 Genethon SA Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Genethon SA Sickle Cell Disease Drug Product Portfolio
- 6.3.5 Genethon SA Recent Developments
- 6.4 Gamida Cell Ltd
- 6.4.1 Gamida Cell Ltd Company Information
- 6.4.2 Gamida Cell Ltd Business Overview
- 6.4.3 Gamida Cell Ltd Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio
- 6.4.5 Gamida Cell Ltd Recent Developments
- 6.5 Errant Gene Therapeutics LLC
- 6.5.1 Errant Gene Therapeutics LLC Company Information
- 6.5.2 Errant Gene Therapeutics LLC Business Overview
- 6.5.3 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio
- 6.5.5 Errant Gene Therapeutics LLC Recent Developments
- 6.6 Editas Medicine Inc
- 6.6.1 Editas Medicine Inc Company Information
- 6.6.2 Editas Medicine Inc Business Overview
- 6.6.3 Editas Medicine Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio
- 6.6.5 Editas Medicine Inc Recent Developments
- 6.7 Daiichi Sankyo Co Ltd
- 6.7.1 Daiichi Sankyo Co Ltd Company Information
- 6.7.2 Daiichi Sankyo Co Ltd Business Overview
- 6.7.3 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio
- 6.7.5 Daiichi Sankyo Co Ltd Recent Developments
- 6.8 CSL Ltd
- 6.8.1 CSL Ltd Company Information
- 6.8.2 CSL Ltd Business Overview
- 6.8.3 CSL Ltd Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 CSL Ltd Sickle Cell Disease Drug Product Portfolio
- 6.8.5 CSL Ltd Recent Developments
- 6.9 CRISPR Therapeutics
- 6.9.1 CRISPR Therapeutics Company Information
- 6.9.2 CRISPR Therapeutics Business Overview
- 6.9.3 CRISPR Therapeutics Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio
- 6.9.5 CRISPR Therapeutics Recent Developments
- 6.10 Calimmune Inc
- 6.10.1 Calimmune Inc Company Information
- 6.10.2 Calimmune Inc Business Overview
- 6.10.3 Calimmune Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Calimmune Inc Sickle Cell Disease Drug Product Portfolio
- 6.10.5 Calimmune Inc Recent Developments
- 6.11 Bristol-Myers Squibb Co
- 6.11.1 Bristol-Myers Squibb Co Company Information
- 6.11.2 Bristol-Myers Squibb Co Business Overview
- 6.11.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio
- 6.11.5 Bristol-Myers Squibb Co Recent Developments
- 6.12 bluebird bio Inc
- 6.12.1 bluebird bio Inc Company Information
- 6.12.2 bluebird bio Inc Business Overview
- 6.12.3 bluebird bio Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 bluebird bio Inc Sickle Cell Disease Drug Product Portfolio
- 6.12.5 bluebird bio Inc Recent Developments
- 6.13 Bioverativ Inc
- 6.13.1 Bioverativ Inc Company Information
- 6.13.2 Bioverativ Inc Business Overview
- 6.13.3 Bioverativ Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 Bioverativ Inc Sickle Cell Disease Drug Product Portfolio
- 6.13.5 Bioverativ Inc Recent Developments
- 6.14 Bio Products Laboratory Ltd
- 6.14.1 Bio Products Laboratory Ltd Company Information
- 6.14.2 Bio Products Laboratory Ltd Business Overview
- 6.14.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.14.4 Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio
- 6.14.5 Bio Products Laboratory Ltd Recent Developments
- 6.15 ArQule Inc
- 6.15.1 ArQule Inc Company Information
- 6.15.2 ArQule Inc Business Overview
- 6.15.3 ArQule Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.15.4 ArQule Inc Sickle Cell Disease Drug Product Portfolio
- 6.15.5 ArQule Inc Recent Developments
- 6.16 Annexin Pharmaceuticals AB
- 6.16.1 Annexin Pharmaceuticals AB Company Information
- 6.16.2 Annexin Pharmaceuticals AB Business Overview
- 6.16.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.16.4 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio
- 6.16.5 Annexin Pharmaceuticals AB Recent Developments
- 6.17 Angiocrine Bioscience Inc
- 6.17.1 Angiocrine Bioscience Inc Company Information
- 6.17.2 Angiocrine Bioscience Inc Business Overview
- 6.17.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.17.4 Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio
- 6.17.5 Angiocrine Bioscience Inc Recent Developments
- 6.18 Addmedica SAS
- 6.18.1 Addmedica SAS Company Information
- 6.18.2 Addmedica SAS Business Overview
- 6.18.3 Addmedica SAS Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.18.4 Addmedica SAS Sickle Cell Disease Drug Product Portfolio
- 6.18.5 Addmedica SAS Recent Developments
- 6.19 Acceleron Pharma Inc
- 6.19.1 Acceleron Pharma Inc Company Information
- 6.19.2 Acceleron Pharma Inc Business Overview
- 6.19.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.19.4 Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio
- 6.19.5 Acceleron Pharma Inc Recent Developments
7 North America by Country
- 7.1 North America Sickle Cell Disease Drug Sales by Country
- 7.1.1 North America Sickle Cell Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Sickle Cell Disease Drug Sales by Country (2021-2026)
- 7.1.3 North America Sickle Cell Disease Drug Sales Forecast by Country (2027-2032)
- 7.2 North America Sickle Cell Disease Drug Market Size by Country
- 7.2.1 North America Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 7.2.3 North America Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Sickle Cell Disease Drug Sales by Country
- 8.1.1 Europe Sickle Cell Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Sickle Cell Disease Drug Sales by Country (2021-2026)
- 8.1.3 Europe Sickle Cell Disease Drug Sales Forecast by Country (2027-2032)
- 8.2 Europe Sickle Cell Disease Drug Market Size by Country
- 8.2.1 Europe Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 8.2.3 Europe Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Sickle Cell Disease Drug Sales by Country
- 9.1.1 Asia-Pacific Sickle Cell Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Sickle Cell Disease Drug Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Sickle Cell Disease Drug Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Sickle Cell Disease Drug Market Size by Country
- 9.2.1 Asia-Pacific Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Sickle Cell Disease Drug Sales by Country
- 10.1.1 South America Sickle Cell Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Sickle Cell Disease Drug Sales by Country (2021-2026)
- 10.1.3 South America Sickle Cell Disease Drug Sales Forecast by Country (2027-2032)
- 10.2 South America Sickle Cell Disease Drug Market Size by Country
- 10.2.1 South America Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 10.2.3 South America Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Sickle Cell Disease Drug Sales by Country
- 11.1.1 Middle East and Africa Sickle Cell Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Sickle Cell Disease Drug Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Sickle Cell Disease Drug Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Sickle Cell Disease Drug Market Size by Country
- 11.2.1 Middle East and Africa Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Sickle Cell Disease Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Sickle Cell Disease Drug Value Chain Analysis
- 12.1.1 Sickle Cell Disease Drug Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Sickle Cell Disease Drug Production Mode & Process
- 12.2 Sickle Cell Disease Drug Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Sickle Cell Disease Drug Distributors
- 12.2.3 Sickle Cell Disease Drug Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,450USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst